PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-27.41%
Both companies show declining cash positions (-27.41% vs GNPX's -19.24%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-27.41%
Cash + STI yoy 1.25-1.5x GNPX's -19.24%. Bruce Berkowitz would check if the firm is preparing for expansions or simply hoarding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.07%
Higher Other Current Assets Growth compared to GNPX's zero value, indicating worse performance.
-28.37%
1.25-1.5x GNPX's -20.36%. Bruce Berkowitz checks if strong current asset growth is used effectively.
1187.39%
≥ 1.5x GNPX's 4.85%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.01%
Less than half of GNPX's -10.78%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
252.00%
≥ 1.5x GNPX's 2.00%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-17.83%
Similar yoy to GNPX's -19.34%. Walter Schloss sees parallel expansions. Evaluate the quality of these assets.
-8.53%
Less than half of GNPX's -30.10%. David Dodd sees a more disciplined AP approach or lower volume.
-29.62%
Higher Short-Term Debt Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
12.29%
Higher Deferred Revenue (Current) Growth compared to GNPX's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-3.44%
Less than half of GNPX's -40.42%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7668.72%
Higher Total Non-Current Liabilities Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
13.42%
Less than half of GNPX's -40.42%. David Dodd sees far fewer liability expansions relative to competitor.
2.97%
1.25-1.5x GNPX's 2.11%. Martin Whitman sees potential dilution risk vs. competitor approach.
-3.03%
Below half GNPX's -7.24%. Michael Burry suspects major net losses or high dividends vs. competitor.
25.83%
Higher AOCI Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-39.38%
≥ 1.5x GNPX's -18.42%. David Dodd sees stronger capital base growth than competitor.
-17.83%
Similar yoy to GNPX's -19.34%. Walter Schloss sees parallel expansions in total capital.
No Data
No Data available this quarter, please select a different quarter.
499.58%
Less than half of GNPX's -73.23%. David Dodd sees less overall debt expansion vs. competitor.
37.73%
Above 1.5x GNPX's 18.66%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.